Evidence map›Paper›PMID 27708768›Full record

ArticleCell & bioscience2016

Roxarsone induces angiogenesis via PI3K/Akt signaling.

Yujing Wang, Donglai Yin, Chao Xu, Kai Wang, Lingmin Zheng, Yumei Zhang

Open access · goldAbstract read
In one paragraph

Article in Cell & bioscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Host angiogenic reprogramming byFrontiers in microbiology · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yujing WangDepartment of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Yangzhou University, 12# Wenhui East Road, Yangzhou, 225009 Jiangsu China.
Donglai YinDepartment of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Yangzhou University, 12# Wenhui East Road, Yangzhou, 225009 Jiangsu China.
Chao XuDepartment of Veterinary Internal Medicine, College of Veterinary Medicine, Yangzhou University, Yangzhou, Jiangsu China.
Kai WangDepartment of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Yangzhou University, 12# Wenhui East Road, Yangzhou, 225009 Jiangsu China.
Lingmin ZhengDepartment of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Yangzhou University, 12# Wenhui East Road, Yangzhou, 225009 Jiangsu China.
Yumei ZhangDepartment of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Yangzhou University, 12# Wenhui East Road, Yangzhou, 225009 Jiangsu China ; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China.
Yangzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background3-Nitro-4-hydroxy phenyl arsenic acid, roxarsone, is widely used as an organic arsenic feed additive for livestock and poultry, which may increase the level of arsenic in the environment and the risk of exposure to arsenic in human. Little information is focused on the angiogenesis roxarsone-induced and its mechanism at present. This paper aims to study the role of PI3K/Akt signaling in roxarsone-induced angiogenesis in rat vascular endothelial cells and a mouse B16-F10 melanoma xenograft model.

resultsThe results showed that treatment with 0.1-10.0 µmol/L roxarsone resulted in an increase in the OD rate in the MTT assay, the number of BrdU-positive cells in the proliferation assay, the migration distance in the scratch test and the number of meshes in tube formation assay. Further, treatment with 1.0 µmol/L roxarsone was associated with significantly higher phosphorylation of PI3K/Akt and expression of VEGF than the control treatment. The PI3K inhibitor was found to significantly combat the effects of 1.0 µmol/L roxarsone. Furthermore, roxarsone treatment was observed to increase the weight and volume of B16-F10 xenografts and VEGF expression and PI3K/Akt phosphorylation in a dose-dependent manner, with the 25 mg/kg dose having significant effects.

conclusionsThese results demonstrate that roxarsone has the ability to promote growth and tube formation in vascular endothelial cells and the growth of mouse B16-F10 xenografts. Further, the findings also indicate that PI3K/Akt signaling plays a regulatory role in roxarsone-induced angiogenesis in vivo and in vitro.

Indexed as

AngiogenesisB16–F10 xenograft modelPI3K/Akt signalingRoxarsoneVascular endothelial cell

Identifiers

PMID27708768
PMCPMC5039879
OpenAlexW2523799709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.